Literature DB >> 24643183

Human papillomavirus infections of the oral mucosa and upper respiratory tract.

Harrison P Nguyen1, Kayla L McNiece, Angela A Duong, Farhan Khan.   

Abstract

Human papillomaviruses (HPVs) are frequently detected in a variety of lesions in the oral mucosa and upper respiratory tract. The pathogenesis in these areas is not as clearly elucidated as in other anatomical regions, but most experts agree that HPVs are responsible for the commonly observed benign lesions, such as squamous papillomas, verruca vulgaris and recurrent respiratory papillomatosis. Transformation of these benign lesions is well described, but it is not clear what role the virus plays, if any, in carcinogenesis. HPV types 6 and 11 are most frequently detected in oral cavity and respiratory tract lesions, though several other types have also been reported. Despite an opaque understanding of these lesions' pathogeneses, it is essential for the clinician to recognize these diseases, to provide appropriate treatment and to promote patient awareness of potential oral transmission. In this paper, we review the major HPV-associated diseases of the oral mucosa and upper respiratory tract, focusing specifically on clinical features, histopathological characteristics and disease management.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24643183     DOI: 10.1159/000357904

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  2 in total

1.  Assessment of awareness of human papillomavirus infection impact on oral cavity among patients.

Authors:  Justyna Oleszkiewicz-Śpiołek; Paulina Adamska; Giulia Marvaso; Barbara A Jereczek-Fossa; Piotr Wychowański; Anna Starzyńska
Journal:  Postepy Dermatol Alergol       Date:  2020-07-23       Impact factor: 1.837

Review 2.  Advancements in the Management of HPV-Associated Head and Neck Squamous Cell Carcinoma.

Authors:  Ross Zeitlin; Harrison P Nguyen; David Rafferty; Stephen Tyring
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.